● AI Equity Research · Healthcare

Aclaris Therapeutics, Inc. (ACRS)

AI stock analysis · Biotechnology · Last analyzed Aug 19, 2026

Compass Score

3.0/5

Call

Hold

Price

$6.30

AI Target

$10.20 +61.9%

AI Analyst Summary

Aclaris Therapeutics is a clinical-stage biotech whose bull thesis rests entirely on pipeline optionality, with 10 of 11 analysts rating it a Buy and a consensus price target implying over 60% upside from current levels. The company's ATI-2138 and related JAK inhibitor pipeline candidates represent meaningful addressable opportunities in inflammatory dermatology, which underpins the strong analyst conviction despite the absence of commercial revenue. The primary risk is binary clinical trial outcomes — a pipeline setback could materially impair the stock with no earnings floor to provide support.

Catalysts

Pipeline data readouts for ATI-2138 (oral JAK inhibitor) expected in upcoming quarters, which could serve as a major re-rating event given 10 bullish analyst mandates.
Potential partnership or licensing deal driven by Phase 2 results, which could provide non-dilutive capital and validate the therapeutic platform.
Continued EPS beat trend in Q3/Q4 results demonstrating cost discipline and extended cash runway, reducing near-term dilution risk.

Risks

Binary clinical risk: failure of lead pipeline assets (ATI-2138 or related candidates) would eliminate the primary value driver with no commercial revenue to cushion the blow, risking a 50%+ stock decline.
Cash burn and dilution risk: as a loss-making company with negative forward P/E of -7.8x, continued operations require capital raises that could significantly dilute existing shareholders.
Revenue contraction: YoY revenue decline of 8.3% signals limited near-term commercial traction; if pipeline timelines slip, the company may face a prolonged cash-intensive development period.

Fundamentals

Pe N/A (loss-making) · 1.0/5

No trailing P/E available; company is loss-making with a negative forward P/E of -7.8x, indicating no near-term path to profitability on current estimates.

Peg N/A · 3.0/5

PEG ratio is unavailable due to negative earnings. Scored neutrally per guidelines, though the lack of profitability is a structural concern.

Analyst Rating Strong Buy consensus (1.3) · 5.0/5

10 Buy / 1 Hold / 0 Sell across 10 analysts with a consensus rating of 1.3 — firmly in Strong Buy territory. High conviction breadth with no sell-side opposition.

Earnings Trend Negative / N/A · 2.0/5

Earnings growth YoY is not available given ongoing losses. Revenue declined 8.3% YoY, reflecting a pipeline-stage company without a meaningful commercial revenue base. EPS beat rate of 3 of 4 quarters provides modest support.

Price Target Beat 3 of 4 quarters (limited history) · 3.0/5

EPS beat rate of 3 of 4 recent quarters is decent but based on only 4 quarters of data, capping this at neutral. Suggests management is controlling costs and losses at or better than expected.

Management Moderate · 3.0/5

Consistent EPS beats on a loss basis suggest reasonable expense discipline, but declining revenue and lack of a commercial product limit confidence in execution. Analyst conviction is high, implying credibility in the pipeline narrative.

● See the full picture

Get today's top-scored picks, ranked for you.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Start free for 3 days →

No credit card. Then $9/month. Cancel anytime.

How Compass scores stocks

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →

Not financial advice. Compass is an analytical tool, not a registered investment adviser or broker-dealer. Scores and recommendations are generated by AI, may be inaccurate or out of date, and are not investment, financial, legal, or tax advice. Investing involves risk, including loss of principal. Do your own research and consult a licensed financial professional. About Compass.